375 related articles for article (PubMed ID: 25805398)
21. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study.
Sutton G; Kauderer J; Carson LF; Lentz SS; Whitney CW; Gallion H;
Gynecol Oncol; 2005 Mar; 96(3):630-4. PubMed ID: 15721404
[TBL] [Abstract][Full Text] [Related]
22. Identification of distinct molecular subtypes of uterine carcinosarcoma.
An Y; Wang H; Jie J; Tang Y; Zhang W; Ji S; Guo X
Oncotarget; 2017 Feb; 8(9):15878-15886. PubMed ID: 28178664
[TBL] [Abstract][Full Text] [Related]
23. The management of patients with uterine sarcoma: a debated clinical challenge.
Gadducci A; Cosio S; Romanini A; Genazzani AR
Crit Rev Oncol Hematol; 2008 Feb; 65(2):129-42. PubMed ID: 17706430
[TBL] [Abstract][Full Text] [Related]
24. Carcinosarcoma of the uterus with melanocytic differentiation.
Kajo K; Zubor P; Spacek J; Ryska A
Pathol Res Pract; 2007; 203(10):753-8. PubMed ID: 17656038
[TBL] [Abstract][Full Text] [Related]
25. Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas.
McCluggage WG
Int J Gynecol Cancer; 2002; 12(6):687-90. PubMed ID: 12445244
[TBL] [Abstract][Full Text] [Related]
26. Uterine carcinosarcoma.
Arend R; Doneza JA; Wright JD
Curr Opin Oncol; 2011 Sep; 23(5):531-6. PubMed ID: 21743326
[TBL] [Abstract][Full Text] [Related]
27. Review of Recommended Treatment of Uterine Carcinosarcoma.
Menczer J
Curr Treat Options Oncol; 2015 Nov; 16(11):53. PubMed ID: 26374341
[TBL] [Abstract][Full Text] [Related]
28. [Clinical analysis of 12 cases of uterine carcinosarcoma].
Wang LH; Xiong Y; Li YF; Li JD; Feng YL; Li YJ; Chen C; Chen L
Ai Zheng; 2008 May; 27(5):516-9. PubMed ID: 18479602
[TBL] [Abstract][Full Text] [Related]
29. Characterizing sarcoma dominance pattern in uterine carcinosarcoma: Homologous versus heterologous element.
Matsuo K; Takazawa Y; Ross MS; Elishaev E; Yunokawa M; Sheridan TB; Bush SH; Klobocista MM; Blake EA; Takano T; Baba T; Satoh S; Shida M; Ikeda Y; Adachi S; Yokoyama T; Takekuma M; Yanai S; Takeuchi S; Nishimura M; Iwasaki K; Johnson MS; Yoshida M; Hakam A; Machida H; Mhawech-Fauceglia P; Ueda Y; Yoshino K; Kajiwara H; Hasegawa K; Yasuda M; Miyake TM; Moriya T; Yuba Y; Morgan T; Fukagawa T; Pejovic T; Nagano T; Sasaki T; Richmond AM; Post MD; Shahzad MMK; Im DD; Yoshida H; Omatsu K; Ueland FR; Kelley JL; Karabakhtsian RG; Roman LD
Surg Oncol; 2018 Sep; 27(3):433-440. PubMed ID: 30217299
[TBL] [Abstract][Full Text] [Related]
30. Uterine and Ovarian Carcinosarcomas: Do They Behave Similarly?
Ureyen I; Karalok A; Cirik DA; Tasci T; Gokce ZK; Duzguner IB; Tulunay G; Turan T
J Obstet Gynaecol Can; 2017 Jul; 39(7):559-563. PubMed ID: 28625283
[TBL] [Abstract][Full Text] [Related]
31. Integrated Molecular Characterization of Uterine Carcinosarcoma.
Cherniack AD; Shen H; Walter V; Stewart C; Murray BA; Bowlby R; Hu X; Ling S; Soslow RA; Broaddus RR; Zuna RE; Robertson G; Laird PW; Kucherlapati R; Mills GB; ; Weinstein JN; Zhang J; Akbani R; Levine DA
Cancer Cell; 2017 Mar; 31(3):411-423. PubMed ID: 28292439
[TBL] [Abstract][Full Text] [Related]
32. The role of lymphadenectomy in uterine leiomyosarcoma: review of the literature and recommendations for the standard surgical procedure.
Dafopoulos A; Tsikouras P; Dimitraki M; Galazios G; Liberis V; Maroulis G; Teichmann AT
Arch Gynecol Obstet; 2010 Sep; 282(3):293-300. PubMed ID: 20502905
[TBL] [Abstract][Full Text] [Related]
33. A multi-institutional cohort study of adjuvant therapy in stage I-II uterine carcinosarcoma.
Cantrell LA; Havrilesky L; Moore DT; O'Malley D; Liotta M; Secord AA; Nagel CI; Cohn DE; Fader AN; Wallace AH; Rose P; Gehrig PA
Gynecol Oncol; 2012 Oct; 127(1):22-6. PubMed ID: 22727985
[TBL] [Abstract][Full Text] [Related]
34. Uterine sarcomas.
Punnonen R; Lauslahti K; Pystynen P; Kauppila O
Ann Chir Gynaecol Suppl; 1985; 197():11-4. PubMed ID: 3863523
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant radiotherapy improves overall survival when added to surgery and chemotherapy for uterine carcinosarcoma: a surveillance, epidemiology, and end results analysis.
Squires BS; Quinn TJ; Nandalur SR; Jawad MS
Int J Clin Oncol; 2021 Dec; 26(12):2282-2294. PubMed ID: 34427803
[TBL] [Abstract][Full Text] [Related]
36. [Carcinosarcomas in female genital tracts: general review].
Guy JB; Trone JC; Casteillo F; Forest F; Pacaut C; Moncharmont C; Espenel S; Vallard A; Langrand Escure J; Collard O; Peoc'h M; Magné N
Bull Cancer; 2014; 101(7-8):760-4. PubMed ID: 25091658
[TBL] [Abstract][Full Text] [Related]
37. Clinical outcome and prognostic factors in 100 cases of uterine sarcoma: experience in Helsinki University Central Hospital 1990-2001.
Koivisto-Korander R; Butzow R; Koivisto AM; Leminen A
Gynecol Oncol; 2008 Oct; 111(1):74-81. PubMed ID: 18657852
[TBL] [Abstract][Full Text] [Related]
38. Uterine carcinosarcoma vs endometrial serous and clear cell carcinoma: A systematic review and meta-analysis of survival.
Raffone A; Travaglino A; Raimondo D; Maletta M; De Vivo V; Visiello U; Casadio P; Seracchioli R; Zullo F; Insabato L; Mollo A
Int J Gynaecol Obstet; 2022 Sep; 158(3):520-527. PubMed ID: 34797919
[TBL] [Abstract][Full Text] [Related]
39. Pathology of mixed Müllerian tumours.
D'Angelo E; Prat J
Best Pract Res Clin Obstet Gynaecol; 2011 Dec; 25(6):705-18. PubMed ID: 21742560
[TBL] [Abstract][Full Text] [Related]
40. Adjuvant Treatment Modalities, Prognostic Factors, and Outcome of the Uterine Carcinosarcoma.
Kahramanoglu I; Demirkiran F; Turan H; Bese T; Cebi S; Ilvan S; Arvas M
J Obstet Gynaecol Can; 2021 Jan; 43(1):34-42. PubMed ID: 33041218
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
